Compare CREX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CREX | PRPO |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 238 | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 44.4M |
| IPO Year | 2015 | 2000 |
| Metric | CREX | PRPO |
|---|---|---|
| Price | $3.90 | $28.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.4K | 12.3K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.86 | ★ 92.15 |
| EPS | N/A | ★ N/A |
| Revenue | $18,437,000.00 | ★ $24,049,000.00 |
| Revenue This Year | $11.51 | N/A |
| Revenue Next Year | $83.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 5.61 | ★ 29.77 |
| 52 Week Low | $1.28 | $5.45 |
| 52 Week High | $4.00 | $29.80 |
| Indicator | CREX | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 66.19 | 54.87 |
| Support Level | $2.22 | $22.96 |
| Resistance Level | N/A | $28.76 |
| Average True Range (ATR) | 0.19 | 1.59 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 93.48 | 72.44 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The Company operates in one reportable segment, marketing technology solutions. The company provides solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.